Loading clinical trials...
Loading clinical trials...
Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Ferring Pharmaceuticals
NCT06372613 · Ulcerative Colitis in Histologic Remission
NCT07550673 · Acute Severe Ulcerative Colitis
NCT07374471 · Ulcerative Colitis (UC)
NCT06071312 · Clostridium Difficile, Ulcerative Colitis
NCT05739864 · Active Ulcerative Colitis
Hospital Brandýs n/Lab.
Brandýs nad Labem
Faculty Hospital U Sv. Anny Brno
Brno
Hospital Břeclav
Břeclav
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions